Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma

被引:34
|
作者
Ding, Yezhou [1 ]
Liu, Kehui [1 ,2 ]
Xu, Yumin [1 ]
Zhao, Qingqing [1 ]
Lou, Shike [1 ]
Xiang, Xiaogang [1 ]
Yan, Lei [1 ]
Cao, Zhujun [1 ]
Xie, Qing [1 ]
Zhu, Chuanwu [3 ]
Bao, Shisan [4 ,5 ]
Wang, Hui [1 ]
机构
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Infect Dis & Hepatol, Sch Med, Shanghai 20025, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Dept Infect Dis, Ruijin Hosp North, Shanghai, Peoples R China
[3] Fifth Peoples Hosp Suzhou, Dept Infect Dis, Suzhou 215007, Jiangsu, Peoples R China
[4] Univ Sydney, Sch Med Sci, Discipline Pathol, Sydney, NSW 2006, Australia
[5] Univ Sydney, Charles Perkin Ctr, Bosch Inst, Sydney, NSW, Australia
来源
CANCER MEDICINE | 2020年 / 9卷 / 09期
基金
中国国家自然科学基金;
关键词
alanine aminotransferase; alpha-fetoprotein; aspartate aminotransferase; hepatocellular carcinoma; neutrophil-lymphocyte ratio; HEPATITIS-B PATIENTS; REDUCED RISK; POPULATION; ENTECAVIR; INDEX; SERUM;
D O I
10.1002/cam4.2968
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Alpha-fetoprotein (AFP), routinely used for diagnosis of hepatocellular carcinoma (HCC), is limited with relatively low sensitivity and high false positivity in HBV-related HCC (HBV-HCC). Thus, an alternative approach was explored to improve specificity/sensitivity for diagnosis of HBV-HCC, using the combination of AFP, inflammatory score, and liver function. Methods Chronic hepatitis B (CHB) (n = 510) and HBV-HCC (n = 473) patients were identified retrospectively for this study. The diagnostic value of single vs combined biomarkers for HBV-HCC was analyzed, using ROC curve. Results It was observed that elderliness, male sex, cirrhosis, HBeAg+ or no-antiviral therapy, and elevation of ALT, AST, neutrophil-lymphocyte ratio (NLR), and AFP were associated with developing HBV-HCC. However, the cut-off ALT defined by Chinese standard, but not by AASLD, was a risk factor. Interestingly, AFP of HBeAg- HBV-HCC patients without cirrhosis was significantly higher than that of the HBeAg+ patients. AUC values for AFP, ALT, AST, or NLR were 0.84 (95% CI: 0.815-0.862), 0.533 (95% CI: 0.501-0.565), 0.696 (95% CI: 0.666-0.725), or 0.684 (95% CI: 0.654-0.713) with optimal cut-off at 7.21 ng/mL, 43 IU/mL, 38 IU/mL, or 2.61, respectively. Combination of AFP with ALT, AST, and NLR improved the diagnostic performance for HBV-HCC, compared to any of the single biomarkers or any other combinations among these patients (except no-cirrhosis). Conclusions Elderliness, male sex, elevated ALT, AST, NLR, AFP, cirrhosis, HBeAg+, and no-antiviral treatment were independent risk factors for HBV-HCC. AASLD standard of ALT cut-off value may not be suitable for the Chinese population. Regular monitoring of HCC among HBeAg- patients with abnormal AFP may improve the management of HBV-HCC. The diagnostic performance of AFP combined with ALT, AST, and NLR for HBV-HCC was superior to single biomarker or any other combinations among these patients, and its diagnostic equation can be used as useful tool for differentiation of HBV-HCC from CHB.
引用
收藏
页码:3057 / 3069
页数:13
相关论文
共 50 条
  • [1] Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma
    Kehui Liu
    Yezhou Ding
    Yun Wang
    Qingqing Zhao
    Lei Yan
    Jingdong Xie
    Yunye Liu
    Qing Xie
    Wei Cai
    Shisan Bao
    Hui Wang
    [J]. Clinical and Experimental Medicine, 2023, 23 : 397 - 409
  • [2] Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma
    Liu, Kehui
    Ding, Yezhou
    Wang, Yun
    Zhao, Qingqing
    Yan, Lei
    Xie, Jingdong
    Liu, Yunye
    Xie, Qing
    Cai, Wei
    Bao, Shisan
    Wang, Hui
    [J]. CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (02) : 397 - 409
  • [3] Combination of AFP, AFP-l3 and PIVKA-II levels improves diagnostic accuracy of hepatocellular carcinoma (ALPS score)
    Lee, Han Ah
    Kim, Tae Hyung
    Lee, Young-Sun
    Jung, Young Kul
    Kim, Ji Hoon
    Yim, Hyung Joon
    Yeon, Jong Eun
    Byun, Kwan Soo
    Um, Soon Ho
    Seo, Yeon Seok
    [J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S371 - S371
  • [4] N-GLYCOME PROFILING IMPROVES DIAGNOSTIC EFFICACIES IN HBV-RELATED HEPATOCELLULAR CARCINOMA
    Gao, C. -F.
    Fang, M.
    Zhao, Y. -P.
    Wang, H.
    Qi, P.
    Chen, C.
    [J]. JOURNAL OF HEPATOLOGY, 2009, 50 : S290 - S290
  • [5] The diagnostic and prognostic implications of PRKRA expression in HBV-related hepatocellular carcinoma
    Yi-Min Hu
    Ruoxi Ran
    Chaoqi Yang
    Song-Mei Liu
    [J]. Infectious Agents and Cancer, 17
  • [6] The diagnostic and prognostic implications of PRKRA expression in HBV-related hepatocellular carcinoma
    Hu, Yi-Min
    Ran, Ruoxi
    Yang, Chaoqi
    Liu, Song-Mei
    [J]. INFECTIOUS AGENTS AND CANCER, 2022, 17 (01)
  • [7] The Study of Menin Expression as a Diagnostic Factor in HBV-Related Hepatocellular Carcinoma
    Moudi, Bita
    Heidari, Zahra
    Mahmoudzadeh-Sagheb, Hamidreza
    [J]. ARCHIVES OF CLINICAL INFECTIOUS DISEASES, 2019, 14 (06):
  • [8] Antiviral therapy improves postoperative survival of patients with HBV-related hepatocellular carcinoma
    Guan, Ruo-Yu
    Sun, Bao-Ye
    Wang, Zhu-Tao
    Zhou, Cheng
    Yang, Zhang-Fu
    Gan, Wei
    Huang, Jin-Long
    Liu, Gao
    Zhou, Jian
    Fan, Jia
    Yi, Yong
    Qiu, Shuang-Jian
    [J]. AMERICAN JOURNAL OF SURGERY, 2022, 224 (01): : 494 - 500
  • [9] C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma
    She, Sha
    Xiang, Yi
    Yang, Min
    Ding, Xiangchun
    Liu, Xiaoyan
    Ma, Lina
    Liu, Qing
    Liu, Bin
    Lu, Zhenhui
    Li, Shiying
    Liu, Yi
    Ran, Xiaoping
    Xu, Xiaoming
    Hu, Huaidong
    Hu, Peng
    Zhang, Dazhi
    Ren, Hong
    Yang, Yixuan
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (02) : 543 - 554
  • [10] Expression of Maspin in HBV-related Hepatocellular Carcinoma
    Moudi, Bita
    Mahmoudzadeh-Sagheb, Hamidreza
    Heidari, Zahra
    [J]. CLINICAL CANCER INVESTIGATION JOURNAL, 2019, 8 (01): : 1 - 6